Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Agendia
The frequency of chemotherapy + endocrine versus endocrine alone decisions in Oncotype DX intermediate score patients will be calculated before and after receiving the MammaPrint result.
Age
18–90
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Women with histologically proven invasive stage I-II, node negative, hormone receptor positive, Her2 negative breast cancer, who received an Oncotype DX intermediate score (18-30)
≥ 18 years of age at time of consent
Written informed consent
You may not be if
Insufficient tissue remaining for Mammaprint FFPE
Tumor sample shipped to Agendia with ≤ 30% tumor cells or that fails QA or QC criteria
Women who have started or completed adjuvant chemotherapy or neo-adjuvant chemotherapy
Clareo Health | PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score
